Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

Am J Respir Crit Care Med. 2023 Jun 1;207(11):1539-1542. doi: 10.1164/rccm.202211-2128LE.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitussive Agents* / adverse effects
  • Chronic Disease
  • Cough* / drug therapy
  • Humans
  • Pyrimidines / therapeutic use
  • Sulfonamides / therapeutic use

Substances

  • Gefapixant
  • Antitussive Agents
  • Pyrimidines
  • Sulfonamides